NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹6.32 Cr | ₹6.24 Cr | ₹8.06 Cr | ₹11 Cr | ₹12 Cr |
What is the latest Total Non-Current Liabilities ratio of NGL FINECHEM ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹6.32 Cr |
Mar2023 | ₹6.24 Cr |
Mar2022 | ₹8.06 Cr |
Mar2021 | ₹11 Cr |
Mar2020 | ₹12 Cr |
How is Total Non-Current Liabilities of NGL FINECHEM Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹6.32 Cr | 1.27 | |
Mar2023 | ₹6.24 Cr | -22.60 | |
Mar2022 | ₹8.06 Cr | -27.82 | |
Mar2021 | ₹11 Cr | -3.92 | |
Mar2020 | ₹12 Cr | - |
Compare Total Non-Current Liabilities of peers of NGL FINECHEM
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NGL FINECHEM | ₹714.9 Cr | -0.3% | 10.2% | -45.6% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹411,306.0 Cr | -2.5% | 7.6% | 4.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹150,343.0 Cr | -3% | 3.4% | 61.5% | Stock Analytics | |
CIPLA | ₹117,323.0 Cr | -1.6% | 3% | -3.4% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹108,619.0 Cr | -0.3% | 9% | 22.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹95,941.5 Cr | -1.2% | 2.9% | -6.4% | Stock Analytics |
NGL FINECHEM Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NGL FINECHEM | -0.3% |
10.2% |
-45.6% |
SENSEX | -1.8% |
2.7% |
5% |
You may also like the below Video Courses